Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth fact...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2012-12, Vol.136 (3), p.795-804 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 804 |
|---|---|
| container_issue | 3 |
| container_start_page | 795 |
| container_title | Breast cancer research and treatment |
| container_volume | 136 |
| creator | Malorni, L. Shetty, P. B. De Angelis, C. Hilsenbeck, S. Rimawi, M. F. Elledge, R. Osborne, C. K. De Placido, S. Arpino, G. |
| description | Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth factor receptor (EGFR) expression. Clinical and biologic features, time to first recurrence (TTFR), and overall survival (OS) were compared in 253 TN versus 1,036 ER positive, PgR positive, HER2-negative [estrogen-driven (ED)] BC. Compared to ED, TN tumors were larger (
p
= 0.02), more proliferative (high S-phase 54 vs. 17 %,
p
|
| doi_str_mv | 10.1007/s10549-012-2315-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3513514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A381054027</galeid><sourcerecordid>A381054027</sourcerecordid><originalsourceid>FETCH-LOGICAL-c598t-7a984a856fd1a777436f9100389d459a00a1bbfe7ea59a7b3beb4540c2ded2533</originalsourceid><addsrcrecordid>eNp1kl2LGyEUhofS0k23_QG9KUJp6c1s1XF05mZhCf2Chd601-I4x4mL0VSdDfn3NSTdTUqLgqjPe47n-FbVa4KvCMbiYyK4ZX2NCa1pQ9p696RakFY0taBEPK0WmHBR8w7zi-pFSncY417g_nl1UWjKmOCLart01lutHFJ-RIMNLkxWIwMqzxESCgblaDcOag-TyvYe0BBBpYy08hpiQtYjhZyKEyAdViHmvWZTUPA5oa3NK-SCn-oMcY1McC5s63nzsnpmlEvw6rheVj8_f_qx_Frffv_ybXlzW-u273ItVN8x1bXcjEQJIVjDTV9qb7p-ZG2vMFZkGAwIUGUnhmaAgbUMazrCSNumuayuD3E387CGUZdHReXkJtq1ijsZlJXnN96u5BTuZdOSMlkJ8OEYIIZfM6Qs1zZpcE55CHOShFLSsY63fUHf_oXehTn6Ul6hOGeMME4fqUk5kNabUPLqfVB503T7H8VUFOrqH1QZI6ytDh6MLedngvcnghUol1cpuDnb4NM5SA6gjiGlCOahGQTLva3kwVay2ErubSV3RfPmtIsPij8-KsC7I6BSMZOJxRw2PXJcEHLg6IFL5cpPEE9a9N_svwHGGOSz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1266441462</pqid></control><display><type>article</type><title>Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Malorni, L. ; Shetty, P. B. ; De Angelis, C. ; Hilsenbeck, S. ; Rimawi, M. F. ; Elledge, R. ; Osborne, C. K. ; De Placido, S. ; Arpino, G.</creator><creatorcontrib>Malorni, L. ; Shetty, P. B. ; De Angelis, C. ; Hilsenbeck, S. ; Rimawi, M. F. ; Elledge, R. ; Osborne, C. K. ; De Placido, S. ; Arpino, G.</creatorcontrib><description>Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth factor receptor (EGFR) expression. Clinical and biologic features, time to first recurrence (TTFR), and overall survival (OS) were compared in 253 TN versus 1,036 ER positive, PgR positive, HER2-negative [estrogen-driven (ED)] BC. Compared to ED, TN tumors were larger (
p
= 0.02), more proliferative (high S-phase 54 vs. 17 %,
p
< 0.0001), more aneuploid (64 vs. 43 %,
p
< 0.0001) and more likely EGFR positive (≥10 fmol/mg by radioligand-binding assay, 49 vs. 7 %,
p
< 0.0001). Among TN, EGFR-positive BC were larger (
p
= 0.0018), more proliferative (
p
< 0.0001), and more aneuploid, (
p
< 0.0001) than EGFR-negative BC. Adjuvant-treated TN patients had shorter TTFR (
p
= 0.0003), and OS (
p
= 0.0017), than ED patients. However, in untreated patients, no differences in TTFR and OS were observed at 8 years median follow-up. Among TN patients, EGFR expression was not associated with worse outcome. TN tumors have a worse outcome in systemically treated patients but not in untreated patients. EGFR expression, does not predict for worse long-term survival.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-012-2315-y</identifier><identifier>PMID: 23124476</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Aged ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer patients ; Cancer research ; Cancer therapies ; Carcinoma, Ductal, Breast - genetics ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - mortality ; Carcinoma, Ductal, Breast - pathology ; Chemotherapy, Adjuvant ; Clinical outcomes ; Clinical Trial ; Comparative analysis ; ErbB Receptors - metabolism ; Estrogen ; Female ; Follow-Up Studies ; Genotype & phenotype ; Gynecology. Andrology. Obstetrics ; Humans ; Long term ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Multivariate Analysis ; Oncology ; Ploidies ; Prognosis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Treatment Outcome ; Tumors</subject><ispartof>Breast cancer research and treatment, 2012-12, Vol.136 (3), p.795-804</ispartof><rights>Springer Science+Business Media New York 2012</rights><rights>2014 INIST-CNRS</rights><rights>COPYRIGHT 2012 Springer</rights><rights>Springer Science+Business Media New York 2012 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c598t-7a984a856fd1a777436f9100389d459a00a1bbfe7ea59a7b3beb4540c2ded2533</citedby><cites>FETCH-LOGICAL-c598t-7a984a856fd1a777436f9100389d459a00a1bbfe7ea59a7b3beb4540c2ded2533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-012-2315-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-012-2315-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26711476$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23124476$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malorni, L.</creatorcontrib><creatorcontrib>Shetty, P. B.</creatorcontrib><creatorcontrib>De Angelis, C.</creatorcontrib><creatorcontrib>Hilsenbeck, S.</creatorcontrib><creatorcontrib>Rimawi, M. F.</creatorcontrib><creatorcontrib>Elledge, R.</creatorcontrib><creatorcontrib>Osborne, C. K.</creatorcontrib><creatorcontrib>De Placido, S.</creatorcontrib><creatorcontrib>Arpino, G.</creatorcontrib><title>Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth factor receptor (EGFR) expression. Clinical and biologic features, time to first recurrence (TTFR), and overall survival (OS) were compared in 253 TN versus 1,036 ER positive, PgR positive, HER2-negative [estrogen-driven (ED)] BC. Compared to ED, TN tumors were larger (
p
= 0.02), more proliferative (high S-phase 54 vs. 17 %,
p
< 0.0001), more aneuploid (64 vs. 43 %,
p
< 0.0001) and more likely EGFR positive (≥10 fmol/mg by radioligand-binding assay, 49 vs. 7 %,
p
< 0.0001). Among TN, EGFR-positive BC were larger (
p
= 0.0018), more proliferative (
p
< 0.0001), and more aneuploid, (
p
< 0.0001) than EGFR-negative BC. Adjuvant-treated TN patients had shorter TTFR (
p
= 0.0003), and OS (
p
= 0.0017), than ED patients. However, in untreated patients, no differences in TTFR and OS were observed at 8 years median follow-up. Among TN patients, EGFR expression was not associated with worse outcome. TN tumors have a worse outcome in systemically treated patients but not in untreated patients. EGFR expression, does not predict for worse long-term survival.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Carcinoma, Ductal, Breast - genetics</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - mortality</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical outcomes</subject><subject>Clinical Trial</subject><subject>Comparative analysis</subject><subject>ErbB Receptors - metabolism</subject><subject>Estrogen</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Genotype & phenotype</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Long term</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Oncology</subject><subject>Ploidies</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kl2LGyEUhofS0k23_QG9KUJp6c1s1XF05mZhCf2Chd601-I4x4mL0VSdDfn3NSTdTUqLgqjPe47n-FbVa4KvCMbiYyK4ZX2NCa1pQ9p696RakFY0taBEPK0WmHBR8w7zi-pFSncY417g_nl1UWjKmOCLart01lutHFJ-RIMNLkxWIwMqzxESCgblaDcOag-TyvYe0BBBpYy08hpiQtYjhZyKEyAdViHmvWZTUPA5oa3NK-SCn-oMcY1McC5s63nzsnpmlEvw6rheVj8_f_qx_Frffv_ybXlzW-u273ItVN8x1bXcjEQJIVjDTV9qb7p-ZG2vMFZkGAwIUGUnhmaAgbUMazrCSNumuayuD3E387CGUZdHReXkJtq1ijsZlJXnN96u5BTuZdOSMlkJ8OEYIIZfM6Qs1zZpcE55CHOShFLSsY63fUHf_oXehTn6Ul6hOGeMME4fqUk5kNabUPLqfVB503T7H8VUFOrqH1QZI6ytDh6MLedngvcnghUol1cpuDnb4NM5SA6gjiGlCOahGQTLva3kwVay2ErubSV3RfPmtIsPij8-KsC7I6BSMZOJxRw2PXJcEHLg6IFL5cpPEE9a9N_svwHGGOSz</recordid><startdate>20121201</startdate><enddate>20121201</enddate><creator>Malorni, L.</creator><creator>Shetty, P. B.</creator><creator>De Angelis, C.</creator><creator>Hilsenbeck, S.</creator><creator>Rimawi, M. F.</creator><creator>Elledge, R.</creator><creator>Osborne, C. K.</creator><creator>De Placido, S.</creator><creator>Arpino, G.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20121201</creationdate><title>Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up</title><author>Malorni, L. ; Shetty, P. B. ; De Angelis, C. ; Hilsenbeck, S. ; Rimawi, M. F. ; Elledge, R. ; Osborne, C. K. ; De Placido, S. ; Arpino, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c598t-7a984a856fd1a777436f9100389d459a00a1bbfe7ea59a7b3beb4540c2ded2533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Carcinoma, Ductal, Breast - genetics</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - mortality</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical outcomes</topic><topic>Clinical Trial</topic><topic>Comparative analysis</topic><topic>ErbB Receptors - metabolism</topic><topic>Estrogen</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Genotype & phenotype</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Long term</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Oncology</topic><topic>Ploidies</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malorni, L.</creatorcontrib><creatorcontrib>Shetty, P. B.</creatorcontrib><creatorcontrib>De Angelis, C.</creatorcontrib><creatorcontrib>Hilsenbeck, S.</creatorcontrib><creatorcontrib>Rimawi, M. F.</creatorcontrib><creatorcontrib>Elledge, R.</creatorcontrib><creatorcontrib>Osborne, C. K.</creatorcontrib><creatorcontrib>De Placido, S.</creatorcontrib><creatorcontrib>Arpino, G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malorni, L.</au><au>Shetty, P. B.</au><au>De Angelis, C.</au><au>Hilsenbeck, S.</au><au>Rimawi, M. F.</au><au>Elledge, R.</au><au>Osborne, C. K.</au><au>De Placido, S.</au><au>Arpino, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2012-12-01</date><risdate>2012</risdate><volume>136</volume><issue>3</issue><spage>795</spage><epage>804</epage><pages>795-804</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth factor receptor (EGFR) expression. Clinical and biologic features, time to first recurrence (TTFR), and overall survival (OS) were compared in 253 TN versus 1,036 ER positive, PgR positive, HER2-negative [estrogen-driven (ED)] BC. Compared to ED, TN tumors were larger (
p
= 0.02), more proliferative (high S-phase 54 vs. 17 %,
p
< 0.0001), more aneuploid (64 vs. 43 %,
p
< 0.0001) and more likely EGFR positive (≥10 fmol/mg by radioligand-binding assay, 49 vs. 7 %,
p
< 0.0001). Among TN, EGFR-positive BC were larger (
p
= 0.0018), more proliferative (
p
< 0.0001), and more aneuploid, (
p
< 0.0001) than EGFR-negative BC. Adjuvant-treated TN patients had shorter TTFR (
p
= 0.0003), and OS (
p
= 0.0017), than ED patients. However, in untreated patients, no differences in TTFR and OS were observed at 8 years median follow-up. Among TN patients, EGFR expression was not associated with worse outcome. TN tumors have a worse outcome in systemically treated patients but not in untreated patients. EGFR expression, does not predict for worse long-term survival.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23124476</pmid><doi>10.1007/s10549-012-2315-y</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2012-12, Vol.136 (3), p.795-804 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3513514 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Biological and medical sciences Breast cancer Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer patients Cancer research Cancer therapies Carcinoma, Ductal, Breast - genetics Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - mortality Carcinoma, Ductal, Breast - pathology Chemotherapy, Adjuvant Clinical outcomes Clinical Trial Comparative analysis ErbB Receptors - metabolism Estrogen Female Follow-Up Studies Genotype & phenotype Gynecology. Andrology. Obstetrics Humans Long term Mammary gland diseases Medical sciences Medicine Medicine & Public Health Middle Aged Multivariate Analysis Oncology Ploidies Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Treatment Outcome Tumors |
| title | Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A58%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20biologic%20features%20of%20triple-negative%20breast%20cancers%20in%20a%20large%20cohort%20of%20patients%20with%20long-term%20follow-up&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Malorni,%20L.&rft.date=2012-12-01&rft.volume=136&rft.issue=3&rft.spage=795&rft.epage=804&rft.pages=795-804&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-012-2315-y&rft_dat=%3Cgale_pubme%3EA381054027%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1266441462&rft_id=info:pmid/23124476&rft_galeid=A381054027&rfr_iscdi=true |